Version 2.1.0.0

Abstract

Abstract: DESCRIPTION (Provided by applicant): Emerging and re-emerging infectious diseases are some of the most important contributors to pain, suffering and poverty in the developing world. For parasitic diseases in general, vaccines are nonexistent and none are likely to have a significant impact in the foreseeable future. In the case of malaria, without a vaccine on the horizon and an increasing prevalence of resistance to commonly used therapeutic drugs, the need for additional anti-malarial drug development is obvious. However, several factors, including increased cost of development, have lead to the retreat of most pharmaceutical companies from the development of new anti-malarial therapeutics. The research and development described in this proposal utilizes a new cost effective approach to anti-malarial drug target discovery. We will use a comparative approach to identify potential therapeutic targets common to Plasmodium falciparum, Toxoplasma gondii and Eimeria tenella. This work will form the basis for a future phase II application, which will use the reagents developed here to identify broad spectrum apicomplexan specific inhibitor compounds.

Thesaurus Terms:
antimalarial agent, drug design /synthesis /production, high throughput technology, immunologic substance development /preparation
Plasmodium falciparum, Toxoplasma gondii, biotherapeutic agent, cost effectiveness, drug discovery /isolation, drug resistance, fungal genetics, genetic library, genome, immunopharmacology, parasitic disease chemotherapy
biotechnology, yeast

Institution:	COMPLEGEN, INC.
	1124 COLUMBIA ST, STE 662
	SEATTLE, WA 98104
Fiscal Year:	2002
Department:
Project Start:	15-APR-2002
Project End:	14-APR-2003
ICD:	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
IRG:	ZRG1